Hamilton Lane Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Hamilton Lane Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-13,929	Closed	-$145K	–	51
2019 Q4	$145K	Hold	13,929	–	–	0.06%	45
2019 Q3	$55K	Hold	13,929	–	–	0.02%	50
2019 Q2	$207K	Hold	13,929	–	–	0.1%	45
2019 Q1	$346K	Buy	+13,929	New	+$349K	0.18%	46
2017 Q3	–	Sell	-10,724	Closed	-$1M	–	63
2017 Q2	$1M	Buy	10,724 +7,170	+202%	+$439K	0.55%	33
2017 Q1	$226K	Buy	+3,554	New	+$216K	0.11%	56
2015 Q4	–	Sell	-20,441	Closed	-$1.88M	–	62
2015 Q3	$1.88M	Sell	20,441 -2,517	-11%	-$218K	0.93%	25
2015 Q2	$2.02M	Buy	+22,958	New	+$1.97M	0.76%	26
2014 Q2	–	Sell	-23,358	Closed	-$1.62M	–	70
2014 Q1	$1.62M	Buy	+23,358	New	+$1.72M	0.65%	33
2013 Q3	–	Sell	-37,654	Closed	-$2.52M	–	61
2013 Q2	$2.52M	Buy	+37,654	New	+$1.69M	1.45%	20

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Hamilton Lane Advisors's CLVS Position: Q1 2020 in Review

Hamilton Lane Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q1 2020, closing a stake of 13,929 shares — an estimated $145K sold.

Hamilton Lane Advisors first reported a position in CLVS in Q2 2013 and held it in 10 quarters. The position peaked at $2.52M in Q2 2013. 154 funds tracked by Wall St. Rank hold CLVS as of Q1 2020.

Hamilton Lane Advisors reported no remaining Clovis Oncology, Inc. position as of Q1 2020 after selling out during the quarter.
Hamilton Lane Advisors sold 13,929 Clovis Oncology, Inc. shares in Q1 2020, an estimated $145K.
Hamilton Lane Advisors first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 10 quarters.
Hamilton Lane Advisors's Clovis Oncology, Inc. position peaked at $2.52M in Q2 2013.
154 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2020.

Based on Hamilton Lane Advisors's 13F filing for Q1 2020, filed 27 Apr 2020.